【摘要】 于2020-09-25,日本药品和医疗器械综合管理机构正式批准5%的Sofpironium bromide凝胶用于治疗多汗症，这是日本首个批准用于治疗原发性腋窝多汗症的局部药物。Sofpironium bromide是由科研製薬株式会社研发的一种具有抗胆碱能作用的外用药物，可通过与汗腺中的M₃受体结合进而减少出汗。本文现从Sofpironium bromide的药理研究、药代动力学、临床研究、安全性等方面进行综述，以全面介绍该药的研究现状和已有成果。更多还原

【Abstract】 On September 25, 2020, Pharmaceuticals and Medical Devices Agency（PMDA） officially approved 5 % Sofpironium bromide gel for the treatment of hyperhidrosis. This is the first topical product approved for the treatment of primary axillary hyperhidrosis in Japan. Sofpironium bromide is a topical drug with anticholinergic effect developed by Kaken Pharmaceutical Co., Ltd. It can reduce sweating by binding to M₃ receptor in the sweat gland that causes hyperhidrosis. The pharmacological study, pharmacokinetics, clinical research, and safety of Sofpironium bromide are reviewed to comprehensively introduce the research status and existing achievements of Sofpironium bromide.更多还原